{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"FDA\", document_type = \"Notice\" and posted_year = 2022 sorted by posted_date descending", "rows": [["FDA-2022-N-2375-0003", "FDA", "FDA-2022-N-2375", "Authorization of Emergency Use of an In Vitro Diagnostic Device in Response to an Outbreak of Mpox; Availability", "Notice", "Announcement", "2022-12-30T05:00:00Z", 2022, 12, "2022-12-30T05:00:00Z", null, "2022-12-30T16:46:00Z", "2022-28460", 0, 0, "0900006485564bf9"], ["FDA-2022-D-3054-0001", "FDA", "FDA-2022-D-3054", "M11 Clinical Electronic Structured Harmonised Protocol; International Council for Harmonisation; Draft Guidance for Industry; Draft Template; and Technical Specification; Availability", "Notice", "Notice of Availability", "2022-12-22T05:00:00Z", 2022, 12, null, null, "2022-12-22T14:20:38Z", "2022-27832", 0, 0, "090000648554d5cb"], ["FDA-2017-D-0085-0044", "FDA", "FDA-2017-D-0085", "Best Practices for Convening a GRAS Panel; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-12-22T05:00:00Z", 2022, 12, "2022-12-22T05:00:00Z", null, "2022-12-22T14:39:30Z", "2022-27714", 0, 0, "090000648554882e"], ["FDA-2022-N-3129-0001", "FDA", "FDA-2022-N-3129", "Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments", "Notice", "Request for Comments", "2022-12-22T05:00:00Z", 2022, 12, "2022-12-22T05:00:00Z", "2023-02-09T04:59:59Z", "2022-12-22T13:43:29Z", "2022-27834", 0, 0, "090000648554d4a4"], ["FDA-2014-D-1167-0024", "FDA", "FDA-2014-D-1167", "Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-12-22T05:00:00Z", 2022, 12, null, null, "2022-12-22T13:50:27Z", "2022-27827", 0, 0, "090000648554d546"], ["FDA-2016-N-0736-0009", "FDA", "FDA-2016-N-0736", "Agency Information Collection Activities; Proposed Collection; Comment Request; Tracking Network for PETNet, LivestockNet, and SampleNet", "Notice", "60 Day Proposed Information Collection", "2022-12-22T05:00:00Z", 2022, 12, "2022-12-22T05:00:00Z", "2023-02-22T04:59:59Z", "2022-12-24T02:00:59Z", "2022-27825", 0, 0, "090000648554d5c4"], ["FDA-2012-D-0530-0038", "FDA", "FDA-2012-D-0530", "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Q-Submission Program for Medical Devices", "Notice", "30 Day Proposed Information Collection", "2022-12-22T05:00:00Z", 2022, 12, "2022-12-22T05:00:00Z", "2023-01-24T04:59:59Z", "2022-12-22T14:51:41Z", "2022-27815", 0, 0, "090000648554d616"], ["FDA-2018-N-0417-0007", "FDA", "FDA-2018-N-0417", "Request for Nominations of Voting Members on a Public Advisory Committee; National Mammography Quality Assurance Advisory Committee", "Notice", "Request for Nominations", "2022-12-22T05:00:00Z", 2022, 12, null, null, "2022-12-22T13:25:37Z", "2022-27883", 0, 0, "090000648554cc75"], ["FDA-2022-N-3208-0001", "FDA", "FDA-2022-N-3208", "Agency Information Collection Activities; Proposed Collection; Comment Request; Records and Reports Concerning Experiences With Approved New Animal Drugs: Adverse Event Reports", "Notice", "60 Day Proposed Information Collection", "2022-12-22T05:00:00Z", 2022, 12, "2022-12-22T05:00:00Z", "2023-02-22T04:59:59Z", "2022-12-24T02:01:01Z", "2022-27817", 0, 0, "090000648554d3b5"], ["FDA-2020-D-1140-0013", "FDA", "FDA-2020-D-1140", "Enforcement Policy Regarding Federal Veterinarian-Client-Patient Relationship Requirements To Facilitate Veterinary Telemedicine During the COVID\u201319 Outbreak; Withdrawal of Guidance", "Notice", "Withdrawal", "2022-12-21T05:00:00Z", 2022, 12, "2022-12-21T05:00:00Z", null, "2022-12-21T20:38:42Z", "2022-27673", 0, 0, "09000064855488d5"], ["FDA-2012-P-1189-0016", "FDA", "FDA-2012-P-1189", "Canned Tuna Deviating From Identity Standard; Amendment of Temporary\nMarketing Permit", "Notice", "General Notice", "2022-12-21T05:00:00Z", 2022, 12, "2022-12-21T05:00:00Z", null, "2022-12-21T20:41:10Z", "2022-27710", 0, 0, "0900006485548da1"], ["FDA-2022-P-0614-0006", "FDA", "FDA-2022-P-0614", "Determination That ZYBAN (Bupropion Hydrochloride) Tablets, Extended\nRelease, 150 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness", "Notice", "Determinations", "2022-12-21T05:00:00Z", 2022, 12, "2022-12-21T05:00:00Z", null, "2022-12-21T15:58:45Z", "2022-27647", 0, 0, "0900006485548d58"], ["FDA-2022-N-2810-0001", "FDA", "FDA-2022-N-2810", "Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments", "Notice", "Meeting", "2022-12-19T05:00:00Z", 2022, 12, "2022-12-19T05:00:00Z", "2023-01-26T04:59:59Z", "2023-01-27T02:00:46Z", "2022-27428", 0, 0, "09000064855400fc"], ["FDA-1998-D-0038-0007", "FDA", "FDA-1998-D-0038", "Evaluating the Safety of Antimicrobial New Animal Drugs With Regard to Their Microbiological Effects on Bacteria of Human Health Concern; Revised Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-12-19T05:00:00Z", 2022, 12, "2022-12-19T05:00:00Z", null, "2022-12-19T13:50:31Z", "2022-27415", 0, 0, "0900006485540064"], ["FDA-2020-N-1206-0004", "FDA", "FDA-2020-N-1206", "Electronic Study Data Submission; Data Standards; Support and Requirement Begin for Study Data Tabulation Model Version 1.7 Implementation Guide 3.3 and for Define-Extensible Markup Language Version 2.1; Requirement Ends for Study Data Tabulation Model Version 1.3 Implementation Guide 3.1.3; Correction", "Notice", "Correction", "2022-12-16T05:00:00Z", 2022, 12, "2022-12-16T05:00:00Z", null, "2022-12-16T14:13:59Z", "2022-27346", 0, 0, "090000648553ca8d"], ["FDA-2013-D-0710-0018", "FDA", "FDA-2013-D-0710", "Circumstances That Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection; Draft Guidance for Industry, Revision 1; Availability", "Notice", "Notice of Availability", "2022-12-16T05:00:00Z", 2022, 12, null, null, "2022-12-16T17:50:05Z", "2022-27344", 0, 0, "090000648553cabe"], ["FDA-2013-D-1319-0009", "FDA", "FDA-2013-D-1319", "Pulmonary Tuberculosis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-12-15T05:00:00Z", 2022, 12, null, null, "2022-12-15T15:05:52Z", "2022-27186", 0, 0, "090000648553845d"], ["FDA-2021-N-0555-1173", "FDA", "FDA-2021-N-0555", "Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals", "Notice", "General Notice", "2022-12-15T05:00:00Z", 2022, 12, "2022-12-15T05:00:00Z", null, "2022-12-15T21:57:11Z", "2022-27192", 0, 0, "0900006485534831"], ["FDA-2012-N-0386-0019", "FDA", "FDA-2012-N-0386", "Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals", "Notice", "General Notice", "2022-12-15T05:00:00Z", 2022, 12, "2022-12-15T05:00:00Z", null, "2022-12-15T21:47:53Z", "2022-27192", 0, 0, "0900006485534369"], ["FDA-2019-N-0430-0009", "FDA", "FDA-2019-N-0430", "Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals", "Notice", "General Notice", "2022-12-15T05:00:00Z", 2022, 12, "2022-12-15T05:00:00Z", null, "2022-12-15T21:51:35Z", "2022-27192", 0, 0, "090000648553436a"], ["FDA-2019-N-5553-0027", "FDA", "FDA-2019-N-5553", "Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals", "Notice", "General Notice", "2022-12-15T05:00:00Z", 2022, 12, "2022-12-15T05:00:00Z", null, "2022-12-15T21:55:28Z", "2022-27192", 0, 0, "0900006485538a84"], ["FDA-2014-N-1048-0013", "FDA", "FDA-2014-N-1048", "Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals", "Notice", "General Notice", "2022-12-15T05:00:00Z", 2022, 12, "2022-12-15T05:00:00Z", null, "2022-12-15T14:39:32Z", "2022-27192", 0, 0, "0900006485538415"], ["FDA-2018-N-3728-0012", "FDA", "FDA-2018-N-3728", "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Collection of Conflict-of-Interest Information for Participation in Food and Drug Administration Non-Employee\nFellowship and Traineeship Programs", "Notice", "30 Day Proposed Information Collection", "2022-12-15T05:00:00Z", 2022, 12, "2022-12-15T05:00:00Z", "2023-01-18T04:59:59Z", "2023-02-14T15:07:07Z", "2022-27194", 0, 0, "09000064855383d6"], ["FDA-2019-N-1517-0009", "FDA", "FDA-2019-N-1517", "Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals", "Notice", "General Notice", "2022-12-15T05:00:00Z", 2022, 12, "2022-12-15T05:00:00Z", null, "2022-12-15T22:04:23Z", "2022-27192", 0, 0, "0900006485538ab6"], ["FDA-2021-N-1050-0019", "FDA", "FDA-2021-N-1050", "Agency Information Collection Activities; Announcement of Office of\nManagement and Budget Approval; Targeted Mechanism of Action Presentations in Prescription Drug Promotion", "Notice", "Notice of Approval", "2022-12-14T05:00:00Z", 2022, 12, "2022-12-14T05:00:00Z", null, "2022-12-14T14:26:43Z", "2022-27140", 0, 0, "090000648553621c"], ["FDA-2022-N-2969-0001", "FDA", "FDA-2022-N-2969", "Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal", "Notice", "Announcement", "2022-12-14T05:00:00Z", 2022, 12, "2022-12-14T05:00:00Z", null, "2022-12-14T15:11:12Z", "2022-27022", 0, 0, "090000648553630a"], ["FDA-2022-N-0521-0002", "FDA", "FDA-2022-N-0521", "David J. Kempema: Final Debarment Order", "Notice", "General Notice", "2022-12-14T05:00:00Z", 2022, 12, "2022-12-14T05:00:00Z", null, "2022-12-14T14:15:33Z", "2022-27091", 0, 0, "09000064855361d1"], ["FDA-2018-N-1262-0017", "FDA", "FDA-2018-N-1262", "Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher", "Notice", "Notice of Approval", "2022-12-14T05:00:00Z", 2022, 12, "2022-12-14T05:00:00Z", null, "2022-12-14T14:00:50Z", "2022-27138", 0, 0, "0900006485535ce4"], ["FDA-2016-N-2544-0013", "FDA", "FDA-2016-N-2544", "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Quality System Regulation", "Notice", "30 Day Proposed Information Collection", "2022-12-13T05:00:00Z", 2022, 12, "2022-12-13T05:00:00Z", "2023-01-13T04:59:59Z", "2022-12-13T16:33:19Z", "2022-27023", 0, 0, "0900006485532492"], ["FDA-2018-N-3091-0003", "FDA", "FDA-2018-N-3091", "Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal", "Notice", "Notice of Renewal", "2022-12-13T05:00:00Z", 2022, 12, "2022-12-13T05:00:00Z", null, "2022-12-13T16:40:16Z", "2022-27014", 0, 0, "0900006485532499"], ["FDA-2012-N-0977-0018", "FDA", "FDA-2012-N-0977", "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents", "Notice", "30 Day Proposed Information Collection", "2022-12-13T05:00:00Z", 2022, 12, "2022-12-13T05:00:00Z", "2023-01-13T04:59:59Z", "2022-12-14T14:28:52Z", "2022-27011", 0, 0, "0900006485532496"], ["FDA-2010-D-0319-0036", "FDA", "FDA-2010-D-0319", "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Dear Healthcare Provider Letters: Improving Communication of Important Safety Information", "Notice", "30 Day Proposed Information Collection", "2022-12-13T05:00:00Z", 2022, 12, "2022-12-13T05:00:00Z", "2023-01-13T04:59:59Z", "2022-12-13T16:37:39Z", "2022-27012", 0, 0, "09000064855324d8"], ["FDA-2022-N-1794-0011", "FDA", "FDA-2022-N-1794", "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; General Drug Labeling Provisions and Over-the-Counter Monograph Drug User Fee Submissions", "Notice", "30 Day Proposed Information Collection", "2022-12-13T05:00:00Z", 2022, 12, "2022-12-13T05:00:00Z", "2023-01-13T04:59:59Z", "2022-12-13T16:35:12Z", "2022-27016", 0, 0, "0900006485532493"], ["FDA-2022-D-2873-0001", "FDA", "FDA-2022-D-2873", "Voluntary Malfunction Summary Reporting Program for Manufacturers; Draft Guidance for Industry and Food and Drug Administration Staff; Availability", "Notice", "Notice of Availability", "2022-12-09T05:00:00Z", 2022, 12, "2022-12-09T05:00:00Z", "2023-02-08T04:59:59Z", "2023-02-08T02:00:44Z", "2022-26729", 0, 0, "090000648552a72e"], ["FDA-2015-D-4599-0007", "FDA", "FDA-2015-D-4599", "Content of Human Factors Information in Medical Device Marketing Submissions; Draft Guidance for Industry and Food and Drug\nAdministration Staff; Availability", "Notice", "Notice of Availability", "2022-12-09T05:00:00Z", 2022, 12, "2022-12-09T05:00:00Z", "2023-03-10T04:59:59Z", "2023-03-11T02:01:16Z", "2022-26767", 0, 0, "090000648552a6ed"], ["FDA-2000-D-0187-0044", "FDA", "FDA-2000-D-0187", "Recommendations To Reduce the Risk of Transfusion-Transmitted Malaria;\nGuidance for Industry; Availability", "Notice", "Notice of Availability", "2022-12-08T05:00:00Z", 2022, 12, "2022-12-08T05:00:00Z", null, "2022-12-08T15:46:19Z", "2022-26711", 0, 0, "0900006485524919"], ["FDA-2022-N-3012-0001", "FDA", "FDA-2022-N-3012", "Teva Branded Pharmaceutical Products R and D, Inc., et al.; Withdrawal of Approval of 35 New Drug Applications", "Notice", "Withdrawal", "2022-12-08T05:00:00Z", 2022, 12, "2022-12-08T05:00:00Z", null, "2022-12-08T15:58:52Z", "2022-26661", 0, 0, "0900006485524e02"], ["FDA-2022-P-0585-0004", "FDA", "FDA-2022-P-0585", "Determination That NORFLEX (Orphenadrine Citrate) Injection, 30 Milligrams/Milliliter, and NORFLEX (Orphenadrine Citrate) Extended-\nRelease Tablet, 100 Milligrams, Were Not Withdrawn From Sale for Reasons\nof Safety or Effectiveness", "Notice", "Determinations", "2022-12-08T05:00:00Z", 2022, 12, "2022-12-08T05:00:00Z", null, "2022-12-08T16:06:44Z", "2022-26663", 0, 0, "0900006485524ea2"], ["FDA-2017-D-6580-48870", "FDA", "FDA-2017-D-6580", "Homeopathic Drug Products; Guidance for Food and Drug Administration Staff and Industry; Availability - Final Guidance", "Notice", "Notice of Availability", "2022-12-07T05:00:00Z", 2022, 12, "2022-12-07T05:00:00Z", null, "2022-12-07T15:57:13Z", "2022-26567", 0, 0, "09000064855212ae"], ["FDA-2018-N-1262-0016", "FDA", "FDA-2018-N-1262", "Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher", "Notice", "Notice of Approval", "2022-12-07T05:00:00Z", 2022, 12, "2022-12-07T05:00:00Z", null, "2022-12-07T16:17:58Z", "2022-26565", 0, 0, "09000064855212b5"], ["FDA-2022-D-2301-0001", "FDA", "FDA-2022-D-2301", "Small Volume Parenteral Drug Products and Pharmacy Bulk Packages for Parenteral Nutrition: Aluminum Content and Labeling Recommendations; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-12-07T05:00:00Z", 2022, 12, "2022-12-07T05:00:00Z", null, "2022-12-07T16:22:42Z", "2022-26564", 0, 0, "0900006485521335"], ["FDA-2021-D-0691-0013", "FDA", "FDA-2021-D-0691", "Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 or Programmed Cell Death-Ligand 1 Blocking Antibodies for Treatment of Patients With Cancer; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-12-06T05:00:00Z", 2022, 12, "2022-12-06T05:00:00Z", null, "2022-12-06T13:06:58Z", "2022-26464", 0, 0, "090000648551cdc8"], ["FDA-2019-D-1828-0008", "FDA", "FDA-2019-D-1828", "E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials; International Council for Harmonisation; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-12-06T05:00:00Z", 2022, 12, "2022-12-06T05:00:00Z", null, "2022-12-06T13:19:55Z", "2022-26433", 0, 0, "090000648551e24f"], ["FDA-2018-N-3236-0002", "FDA", "FDA-2018-N-3236", "Advisory Committee; Oncologic Drugs Advisory Committee; Renewal", "Notice", "Notice of Renewal", "2022-12-05T05:00:00Z", 2022, 12, "2022-12-05T05:00:00Z", null, "2022-12-05T13:26:51Z", "2022-26363", 0, 0, "09000064855195b3"], ["FDA-2017-D-3101-0017", "FDA", "FDA-2017-D-3101", "Abbreviated New Drug Applications: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-12-05T05:00:00Z", 2022, 12, "2022-12-05T05:00:00Z", null, "2022-12-05T13:29:25Z", "2022-26412", 0, 0, "09000064855196fa"], ["FDA-2001-D-0197-0002", "FDA", "FDA-2001-D-0197", "Statistical Approaches To Establishing Bioequivalence; Draft Guidance for\nIndustry; Availability", "Notice", "Notice of Availability", "2022-12-05T05:00:00Z", 2022, 12, "2022-12-05T05:00:00Z", null, "2022-12-05T13:39:43Z", "2022-26414", 0, 0, "09000064855195b1"], ["FDA-2022-Z-0025-0003", "FDA", "FDA-2022-Z-0025", "Statement of Organization, Functions,\nand Delegations of Authority", "Notice", "General Notice", "2022-12-02T05:00:00Z", 2022, 12, "2022-12-02T05:00:00Z", null, "2022-12-02T14:54:14Z", "2022-26280", 0, 0, "0900006485511aa6"], ["FDA-2022-N-3072-0001", "FDA", "FDA-2022-N-3072", "Virtual Public Meeting: FDA Rare Disease Day 2023 Information", "Notice", "Meeting", "2022-12-02T05:00:00Z", 2022, 12, "2022-12-02T05:00:00Z", "2023-04-08T03:59:59Z", "2023-04-08T01:01:40Z", null, 0, 0, "0900006485513275"], ["FDA-2018-N-3233-0005", "FDA", "FDA-2018-N-3233", "Requests for Nominations: Voting Members on a Public Advisory Committee; Technical Electronic Product Radiation Safety Standards Committee", "Notice", "Request for Nominations", "2022-12-01T05:00:00Z", 2022, 12, "2022-12-01T05:00:00Z", null, "2022-12-01T13:20:08Z", "2022-26125", 0, 0, "090000648550e731"], ["FDA-2022-D-2899-0001", "FDA", "FDA-2022-D-2899", "Effectiveness of Anthelmintics: Specific Recommendations for Products Proposed for the Prevention of Heartworm Disease in Dogs; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-11-30T05:00:00Z", 2022, 11, "2022-11-30T05:00:00Z", null, "2022-11-30T16:17:29Z", "2022-26059", 0, 0, "090000648550a1ef"], ["FDA-2022-D-0099-0001", "FDA", "FDA-2022-D-0099", "Questions and Answers Regarding Food Allergens, Including the Food Allergen Labeling Requirements of the Federal Food, Drug, and Cosmetic Act (Edition 5): Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-11-30T05:00:00Z", 2022, 11, "2022-11-30T05:00:00Z", null, "2022-11-30T16:52:53Z", "2022-26110", 0, 0, "090000648550a242"], ["FDA-2022-N-2855-0001", "FDA", "FDA-2022-N-2855", "Mylan Institutional, Inc.; Withdrawal of Approval of a New Drug Application for SULFAMYLON\u00ae (Mafenide Acetate, USP) Powder for 5% Topical Solution", "Notice", "Withdrawal", "2022-11-30T05:00:00Z", 2022, 11, "2022-11-30T05:00:00Z", null, "2022-11-30T14:46:10Z", "2022-26057", 0, 0, "090000648550a1ec"], ["FDA-2013-D-0811-0153", "FDA", "FDA-2013-D-0811", "Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation To Treat Clostridioides difficile Infection Not Responsive to Standard Therapies; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-11-29T05:00:00Z", 2022, 11, "2022-11-29T05:00:00Z", null, "2022-11-29T15:13:37Z", "2022-26000", 0, 0, "0900006485507229"], ["FDA-2022-N-1129-0003", "FDA", "FDA-2022-N-1129", "Jennings Ryan Staley: Final Debarment Order", "Notice", "Statutory Debarment", "2022-11-29T05:00:00Z", 2022, 11, "2022-11-29T05:00:00Z", null, "2024-11-12T23:47:21Z", "2022-26012", 1, 0, "0900006485507afb"], ["FDA-2019-N-3926-0006", "FDA", "FDA-2019-N-3926", "Request for Nominations for Voting Members on Public Advisory Panels of the Medical Devices Advisory Committee", "Notice", "Request for Nominations", "2022-11-28T05:00:00Z", 2022, 11, "2022-11-28T05:00:00Z", null, "2022-11-28T16:40:21Z", "2022-25813", 0, 0, "0900006485504549"], ["FDA-2022-N-2782-0001", "FDA", "FDA-2022-N-2782", "Antimicrobial Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments", "Notice", "Request for Comments", "2022-11-25T05:00:00Z", 2022, 11, "2022-11-25T05:00:00Z", "2023-01-24T04:59:59Z", "2023-01-04T02:00:57Z", "2022-25643", 0, 0, "0900006485500677"], ["FDA-2018-N-1262-0015", "FDA", "FDA-2018-N-1262", "Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher", "Notice", "Notice of Approval", "2022-11-25T05:00:00Z", 2022, 11, "2022-11-25T05:00:00Z", null, "2022-11-25T14:45:36Z", "2022-25644", 0, 0, "0900006485500679"], ["FDA-2022-N-2825-0001", "FDA", "FDA-2022-N-2825", "Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments", "Notice", "Request for Comments", "2022-11-25T05:00:00Z", 2022, 11, "2022-11-25T05:00:00Z", "2023-01-07T04:59:59Z", "2022-12-15T02:00:31Z", "2022-25642", 0, 0, "09000064855005e6"], ["FDA-2018-N-3240-0369", "FDA", "FDA-2018-N-3240", "List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act", "Notice", "General Notice", "2022-11-23T05:00:00Z", 2022, 11, "2022-11-23T05:00:00Z", "2023-01-24T04:59:59Z", "2023-01-24T02:01:08Z", "2022-25549", 0, 0, "09000064854fe4c0"], ["FDA-2022-D-2922-0001", "FDA", "FDA-2022-D-2922", "Compounding Certain Beta-Lactam Products in Shortage Under Section\n503A of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry;\nAvailability", "Notice", "Guidance", "2022-11-23T05:00:00Z", 2022, 11, "2022-11-23T05:00:00Z", null, "2022-11-23T14:38:36Z", "2022-25622", 0, 0, "09000064854fe37a"], ["FDA-2022-N-2796-0001", "FDA", "FDA-2022-N-2796", "Bristol Myers Products Inc.; Proposal To Withdraw Approval of a New Drug\nApplication for Bufferin (Aspirin) Tablets; Opportunity for a Hearing", "Notice", "Withdrawal", "2022-11-23T05:00:00Z", 2022, 11, "2022-11-23T05:00:00Z", "2023-01-24T04:59:59Z", "2023-02-02T19:29:11Z", "2022-25516", 0, 0, "09000064854fe483"], ["FDA-2022-N-2841-0001", "FDA", "FDA-2022-N-2841", "Science Board to the Food and Drug Administration Advisory Committee; Notice of Meeting", "Notice", "Advisory Committee", "2022-11-22T05:00:00Z", 2022, 11, "2022-11-22T05:00:00Z", null, "2022-11-22T16:45:04Z", "2022-25405", 0, 0, "09000064854fb9dc"], ["FDA-2022-N-2657-0001", "FDA", "FDA-2022-N-2657", "Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug Administration\u2019s Study of Assessing Physiological, Neural and Self-Reported Response to Tobacco Education Messages", "Notice", "60 Day Proposed Information Collection", "2022-11-22T05:00:00Z", 2022, 11, "2022-11-22T05:00:00Z", "2023-01-24T04:59:59Z", "2023-01-08T03:41:08Z", "2022-25406", 0, 0, "09000064854fbad4"], ["FDA-2022-N-0009-0007", "FDA", "FDA-2022-N-0009", "Statement of Organization, Functions, and Delegations of Authority; Correction", "Notice", "Correction", "2022-11-22T05:00:00Z", 2022, 11, "2022-11-22T05:00:00Z", null, "2022-11-22T15:38:32Z", "2022-25409", 0, 0, "09000064854fba49"], ["FDA-2011-N-0656-1300", "FDA", "FDA-2011-N-0656", "Animal Drug User Fee Act; Public Meeting; Request for Comments", "Notice", "Request for Comments", "2022-11-21T05:00:00Z", 2022, 11, "2022-11-21T05:00:00Z", "2022-12-20T04:59:59Z", "2022-12-21T02:01:20Z", "2022-25274", 0, 0, "09000064854ef8f2"], ["FDA-2022-N-2826-0001", "FDA", "FDA-2022-N-2826", "Allergan Sales, LLC, et al.; Withdrawal of Approval of 10 Abbreviated New Drug Applications", "Notice", "Withdrawal", "2022-11-21T05:00:00Z", 2022, 11, "2022-11-21T05:00:00Z", null, "2022-11-21T13:23:13Z", "2022-25315", 0, 0, "09000064854f814f"], ["FDA-2007-D-0369-0693", "FDA", "FDA-2007-D-0369", "Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability", "Notice", "Notice of Availability", "2022-11-18T05:00:00Z", 2022, 11, "2022-11-18T05:00:00Z", null, "2023-02-17T15:36:29Z", "2022-25210", 0, 0, "09000064854d0520"], ["FDA-2022-N-2672-0002", "FDA", "FDA-2022-N-2672", "Draft Amended Environmental Assessment for Production of AquAdvantage Salmon at the Bay Fortune and Rollo Bay Facilities on Prince Edward Island, Canada; Public Meeting; Request for Comments", "Notice", "Public Meetings", "2022-11-17T05:00:00Z", 2022, 11, "2022-11-17T05:00:00Z", "2023-01-18T04:59:59Z", "2023-01-24T02:01:08Z", "2022-25002", 0, 0, "09000064854bdfde"], ["FDA-2022-N-2672-0003", "FDA", "FDA-2022-N-2672", "Draft Amended Environmental Assessment for Production of AquAdvantage Salmon at the Bay Fortune and Rollo Bay Facilities on Prince Edward Island, Canada; Availability; Request for Comments", "Notice", "Notice of Availability", "2022-11-17T05:00:00Z", 2022, 11, "2022-11-17T05:00:00Z", "2023-01-18T04:59:59Z", "2023-01-19T02:01:06Z", "2022-25001", 0, 0, "09000064854bdfe4"], ["FDA-2022-N-2673-0001", "FDA", "FDA-2022-N-2673", "Safety and Effectiveness of Certain Naloxone Hydrochloride Drug Products for Nonprescription Use; Request for Comments", "Notice", "Request for Comments", "2022-11-16T05:00:00Z", 2022, 11, "2022-11-16T05:00:00Z", "2023-01-18T04:59:59Z", "2023-01-19T02:00:34Z", "2022-24874", 0, 0, "09000064854bb10e"], ["FDA-2019-N-2778-0005", "FDA", "FDA-2019-N-2778", "Agency Information Collection Activities; Submission for Office of\nManagement and Budget Review; Comment Request; Threshold of Regulation for Substances Used in Food-Contact Articles", "Notice", "30 Day Proposed Information Collection", "2022-11-15T05:00:00Z", 2022, 11, "2022-11-15T05:00:00Z", null, "2022-11-15T15:54:09Z", "2022-24801", 0, 0, "09000064854b0d9e"], ["FDA-2021-N-0526-0002", "FDA", "FDA-2021-N-0526", "David Elias Mendoza: Final Debarment Order", "Notice", "General Notice", "2022-11-15T05:00:00Z", 2022, 11, "2022-11-15T05:00:00Z", null, "2022-11-15T15:10:50Z", "2022-24805", 0, 0, "09000064854b0d10"], ["FDA-2022-D-2512-0001", "FDA", "FDA-2022-D-2512", "Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin; International Council for Harmonisation; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-11-14T05:00:00Z", 2022, 11, "2022-11-14T05:00:00Z", null, "2022-11-14T16:04:58Z", "2022-24685", 0, 0, "09000064854aab74"], ["FDA-2019-E-2271-0006", "FDA", "FDA-2019-E-2271", "Determination of Regulatory Review Period for Purposes of Patent Extension; PREVYMIS IV Solution, New Drug Application 209940", "Notice", "Determinations", "2022-11-14T05:00:00Z", 2022, 11, "2022-11-14T05:00:00Z", "2023-01-14T04:59:59Z", "2022-11-14T16:28:59Z", "2022-24719", 0, 0, "09000064854aac1b"], ["FDA-2021-D-0997-0006", "FDA", "FDA-2021-D-0997", "Referencing the Definition of \u2018\u2018Device\u2019\u2019 in the Federal Food, Drug, and Cosmetic Act in Guidance, Regulatory Documents, Communications, and\nOther Public Documents; Guidance for Industry and Food and Drug Administration Staff; Availability - Final Guidance", "Notice", "Notice of Availability", "2022-11-14T05:00:00Z", 2022, 11, "2022-11-14T05:00:00Z", null, "2022-11-14T15:38:42Z", "2022-24707", 0, 0, "09000064854aaa05"], ["FDA-2019-E-2273-0006", "FDA", "FDA-2019-E-2273", "Determination of Regulatory Review Period for Purposes of Patent Extension; PREVYMIS, New Drug Application 209939", "Notice", "Determinations", "2022-11-14T05:00:00Z", 2022, 11, "2022-11-14T05:00:00Z", "2023-01-14T04:59:59Z", "2022-11-14T15:02:40Z", "2022-24718", 0, 0, "09000064854aa583"], ["FDA-2016-N-2683-0012", "FDA", "FDA-2016-N-2683", "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Data To Support\nSocial and Behavioral Research as Used by the Food and Drug Administration", "Notice", "30 Day Proposed Information Collection", "2022-11-14T05:00:00Z", 2022, 11, "2022-11-14T05:00:00Z", null, "2022-11-14T18:04:53Z", "2022-24693", 0, 0, "09000064854aa9fd"], ["FDA-2022-D-0697-0001", "FDA", "FDA-2022-D-0697", "Sameness Evaluations in an Abbreviated New Drug Application\u2014Active Ingredients; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-11-09T05:00:00Z", 2022, 11, "2022-11-09T05:00:00Z", null, "2022-11-09T13:49:02Z", "2022-24432", 0, 0, "090000648549d539"], ["FDA-2020-E-2046-0005", "FDA", "FDA-2020-E-2046", "Determination of Regulatory Review Period for Purposes of Patent Extension; NEXLETOL", "Notice", "Determinations", "2022-11-09T05:00:00Z", 2022, 11, "2022-11-09T05:00:00Z", "2023-01-10T04:59:59Z", "2022-11-10T02:00:26Z", "2022-24431", 0, 0, "090000648549d0f5"], ["FDA-2020-E-2257-0006", "FDA", "FDA-2020-E-2257", "Determination of Regulatory Review Period for Purposes of Patent Extension; XCOPRI", "Notice", "Determinations", "2022-11-09T05:00:00Z", 2022, 11, "2022-11-09T05:00:00Z", "2023-01-10T04:59:59Z", "2022-11-10T02:00:38Z", "2022-24457", 0, 0, "090000648549d5cd"], ["FDA-2022-N-2174-0002", "FDA", "FDA-2022-N-2174", "Oncologic Drugs Advisory Committee; Cancellation", "Notice", "Meeting", "2022-11-09T05:00:00Z", 2022, 11, "2022-11-09T05:00:00Z", null, "2022-11-09T13:40:59Z", "2022-24470", 0, 0, "090000648549d61a"], ["FDA-2021-E-0381-0006", "FDA", "FDA-2021-E-0381", "Determination of Regulatory Review Period for Purposes of Patent Extension; TISSUEBLUE", "Notice", "Determinations", "2022-11-09T05:00:00Z", 2022, 11, "2022-11-09T05:00:00Z", "2023-01-10T04:59:59Z", "2022-11-09T13:42:05Z", "2022-24434", 0, 0, "090000648549d0f1"], ["FDA-2020-E-1995-0005", "FDA", "FDA-2020-E-1995", "Determination of Regulatory Review Period for Purposes of Patent Extension; NOURIANZ", "Notice", "Determinations", "2022-11-07T05:00:00Z", 2022, 11, "2022-11-07T05:00:00Z", "2023-01-07T04:59:59Z", "2022-11-07T18:21:13Z", "2022-24217", 0, 0, "0900006485492c81"], ["FDA-2016-N-2066-0008", "FDA", "FDA-2016-N-2066", "Agency Information Collection Activities; Proposed Collection; Comment Request; Certification of Identity for Freedom of Information Act and Privacy Act Requests", "Notice", "60 Day Proposed Information Collection", "2022-11-07T05:00:00Z", 2022, 11, "2022-11-07T05:00:00Z", "2023-01-07T04:59:59Z", "2022-11-07T13:49:02Z", "2022-24110", 0, 0, "0900006485492c80"], ["FDA-2021-D-0776-0013", "FDA", "FDA-2021-D-0776", "Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial; Guidance for Industry; Availability", "Notice", "Guidance", "2022-11-07T05:00:00Z", 2022, 11, "2022-11-07T05:00:00Z", null, "2022-11-07T13:31:59Z", "2022-24112", 0, 0, "0900006485492c29"], ["FDA-2022-N-2671-0001", "FDA", "FDA-2022-N-2671", "Drug Supply Chain Security Act Implementation and Readiness Efforts for 2023; Public Meeting; Request for Comments", "Notice", "Request for Comments", "2022-11-07T05:00:00Z", 2022, 11, "2022-11-07T05:00:00Z", "2023-02-07T04:59:59Z", "2023-02-25T02:00:19Z", "2022-24212", 0, 0, "0900006485492dea"], ["FDA-2018-E-4324-0003", "FDA", "FDA-2018-E-4324", "Determination of Regulatory Review Period for Purposes of Patent Extension; ANGELMED GUARDIAN SYSTEM", "Notice", "Determinations", "2022-11-07T05:00:00Z", 2022, 11, "2022-11-07T05:00:00Z", "2023-01-07T04:59:59Z", "2022-11-07T13:39:11Z", "2022-24216", 0, 0, "0900006485492c7c"], ["FDA-2013-N-0557-0010", "FDA", "FDA-2013-N-0557", "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Postmarket Surveillance of Medical Devices", "Notice", "30 Day Proposed Information Collection", "2022-11-07T05:00:00Z", 2022, 11, "2022-11-07T05:00:00Z", "2022-12-08T04:59:59Z", "2022-11-07T18:23:16Z", "2022-24232", 0, 0, "0900006485492deb"], ["FDA-2019-D-1469-0015", "FDA", "FDA-2019-D-1469", "M10 Bioanalytical Method Validation and Study Sample Analysis; International Council for Harmonisation; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-11-07T05:00:00Z", 2022, 11, "2022-11-07T05:00:00Z", null, "2022-11-07T13:45:18Z", "2022-24113", 0, 0, "0900006485492c7d"], ["FDA-2010-D-0350-0033", "FDA", "FDA-2010-D-0350", "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Tobacco Retailer Training Programs", "Notice", "30 Day Proposed Information Collection", "2022-11-07T05:00:00Z", 2022, 11, "2022-11-07T05:00:00Z", null, "2022-11-07T15:17:07Z", "2022-24218", 0, 0, "0900006485492c7a"], ["FDA-2020-E-1994-0005", "FDA", "FDA-2020-E-1994", "Determination of Regulatory Review Period for Purposes of Patent Extension; NOURIANZ", "Notice", "Determinations", "2022-11-07T05:00:00Z", 2022, 11, "2022-11-07T05:00:00Z", "2023-01-07T04:59:59Z", "2022-11-07T18:20:20Z", "2022-24217", 0, 0, "0900006485489888"], ["FDA-2022-N-0150-0007", "FDA", "FDA-2022-N-0150", "Revocation of Two Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID\u201319; Availability", "Notice", "Announcement", "2022-11-04T04:00:00Z", 2022, 11, "2022-11-04T04:00:00Z", null, "2022-11-04T14:25:30Z", "2022-24072", 0, 0, "09000064854883e3"], ["FDA-2022-N-1961-0038", "FDA", "FDA-2022-N-1961", "Advancing Premarket Safety Analytics Workshop; Request for Comments", "Notice", "Request for Comments", "2022-11-03T04:00:00Z", 2022, 11, "2022-11-03T04:00:00Z", "2022-12-06T04:59:59Z", "2022-12-07T02:01:18Z", "2022-23925", 0, 0, "090000648548119a"], ["FDA-2020-D-2107-0009", "FDA", "FDA-2020-D-2107", "Cross Labeling Oncology Drugs in Combination Regimens; Guidance for\nIndustry; Availability", "Notice", "Notice of Availability", "2022-11-03T04:00:00Z", 2022, 11, "2022-11-03T04:00:00Z", null, "2022-11-03T12:37:22Z", "2022-23866", 0, 0, "09000064854812db"], ["FDA-2021-N-0341-0006", "FDA", "FDA-2021-N-0341", "Agency Information Collection Activities; Proposed Collection; Comment Request; Federal-State Food Regulatory Program Standards", "Notice", "60 Day Proposed Information Collection", "2022-11-03T04:00:00Z", 2022, 11, "2022-11-03T04:00:00Z", "2023-01-04T04:59:59Z", "2023-01-04T02:01:00Z", "2022-23919", 0, 0, "09000064854811e2"], ["FDA-2022-D-2336-0001", "FDA", "FDA-2022-D-2336", "Assessing User Fees Under the Overthe-Counter Monograph Drug User Fee Program; Draft Guidance for Industry;\nAvailability", "Notice", "Notice of Availability", "2022-11-02T04:00:00Z", 2022, 11, null, null, "2022-11-02T12:14:05Z", "2022-23791", 0, 0, "090000648547b381"], ["FDA-2013-N-0796-0012", "FDA", "FDA-2013-N-0796", "Agency Information Collection Activities; Proposed Collection; Comment Request; Testing Communications by the Food and Drug Administration\u2019s Center for Devices and Radiological Health", "Notice", "60 Day Proposed Information Collection", "2022-11-02T04:00:00Z", 2022, 11, "2022-11-02T04:00:00Z", "2023-01-04T04:59:59Z", "2022-11-02T14:44:21Z", "2022-23781", 0, 0, "090000648547b419"], ["FDA-2021-D-0669-0008", "FDA", "FDA-2021-D-0669", "S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals; International Council for Harmonisation; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-11-02T04:00:00Z", 2022, 11, null, null, "2022-11-02T12:34:04Z", "2022-23787", 0, 0, "090000648547b3db"], ["FDA-2013-D-0446-0015", "FDA", "FDA-2013-D-0446", "Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-11-02T04:00:00Z", 2022, 11, null, null, "2022-11-02T13:00:13Z", "2022-23785", 0, 0, "090000648547b466"], ["FDA-2016-N-3535-0009", "FDA", "FDA-2016-N-3535", "Agency Information Collection Activities; Proposed Collection; Comment Request; Special Protocol Assessment; Guidance for Industry", "Notice", "60 Day Proposed Information Collection", "2022-11-01T04:00:00Z", 2022, 11, "2022-11-01T04:00:00Z", "2023-01-04T04:59:59Z", "2023-01-05T02:00:51Z", "2022-23727", 0, 0, "0900006485477988"]], "truncated": false, "filtered_table_rows_count": 827, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 and \"document_type\" = :p1 and \"posted_year\" = :p2 order by posted_date desc limit 101", "params": {"p0": "FDA", "p1": "Notice", "p2": "2022"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2022", "results": [{"value": "FDA", "label": "FDA", "count": 827, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?document_type=Notice&posted_year=2022", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2022", "results": [{"value": "Notice", "label": "Notice", "count": 827, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&posted_year=2022", "selected": true}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2022", "results": [{"value": 2022, "label": 2022, "count": 827, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2022&_facet=subtype"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2022&_facet=posted_month"}, {"name": "open_for_comment", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2022&_facet=open_for_comment"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2022&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2022&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2022&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2022&_facet_date=last_modified"}], "next": "2022-11-01T04~3A00~3A00Z,FDA-2016-N-3535-0009", "next_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2022&_next=2022-11-01T04~3A00~3A00Z%2CFDA-2016-N-3535-0009&_sort_desc=posted_date", "private": false, "allow_execute_sql": true, "query_ms": 921.2558770086616, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}